Please assess the completion status of the following clinical trial:

Trial Title: Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 years~* Obese patients with Body Mass Index between 30 and 35~* Patients who, regardless of their inclusion in this study, are going to follow the standardized weight-loss programme (PronoKal® Method)~* Patients who agree to participate and sign the Informed Consent form~Exclusion Criteria:~* Treatment with Omega-3 fatty acid supplements for other reasons during the month prior to inclusion in the trial~* Treatment with acetylsalicylic acid (ASA), non-steroidal anti-inflammatory drugs (NSAIDS), corticoids or thiazolidinedione antidiabetic drugs (glitazones)~* Pregnant or nursing patients~* Haemopathy, including clotting disorders~* Treatment with dicoumarin anticoagulants (Sintrom®)~* Cancer or a history of cancer who have not received the oncologist's release~* Type 1 or type 2 diabetes mellitus~* Immune disorders (rheumatoid arthritis, lupus, etc.) and/or inflammatory disease (ulcerative colitis, Crohn's disease, etc.) that may alter the biological markers of inflammation~* Patients not expected to attend monitoring visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- omega-3 DHA (Type: ACTIVE_COMPARATOR): Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
- Control (Type: PLACEBO_COMPARATOR): Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme

Based on this trial design, predict the completion outcome and termination type (if applicable).